Metastasis-directed radiation therapy plus hormone therapy improves PFS for men with advanced prostate cancer

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

October 30, 2026

Vol.52 No.40

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

A multi-center clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence, and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Researchers uncovers immune driver of radiation-related lung injury, City of Hope-led preclinical study finds

Researchers at City of Hope have uncovered an immune pathway that may contribute to radiation-related lung damage and have identified a potential strategy to block it. The insights from the preclinical study could lead to treatments that prevent radiation from harming healthy lung tissue and improve patients’ quality of life.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT, or androgen deprivation therapy, to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence, according to a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.

October 02, 2026

Vol.52 No.36

Metastasis-directed radiation therapy plus hormone therapy improves PFS for men with advanced prostate cancer

YOU MAY BE INTERESTED IN

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

Researchers uncovers immune driver of radiation-related lung injury, City of Hope-led preclinical study finds

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login